Vision Source; Blazing the Trail for AMD Management


My name is Aaron Werner and I’m an optometrist
here and recent owner of the practice. The practice was started by dad over 35
years ago and I’m actually fifth generation optometrists so I did everything I could
not to be here and here I am. But it’s in the blood and I love it. The practice sees, altogether, about 250 comprehensive eye exams a month so I
think the AdaptDx will change how we talk about AMD and AMD outcomes. We don’t do a good enough job saving the first eye on patients and we do a fantastic job saving
second eye. It’s not a sexy disease. I don’t think it gets the attention that it deserves but we definitely need to to focus on how we are treating this
disease and I would not be surprised if dark adaptation becomes standard of
care in the disease process. Similar to how having an OCT or an ultra-wide
field is kind of becoming standard of care of how we treat retinal diseases. But
I think Vision Source is primed to take the lead in the diagnosis and management of AMD. As an organization, we have the infrastructure for the education, we are incredibly forward-thinking in medical optometry, not only are we used to
technology but we love technology. We’re on the forefront of research. We’ve got Vision Source and people leading the way really in all aspects of the profession,
but we need to reduce the cost to the healthcare system and treating AMD early, saving vision, and treating it with nutraceuticals instead of having expensive injections. And the cost to the patients and employers,
you know, who’ve missed work and whatnot. This is really a no-brainer. And Vision Source is exactly where we need to be to take the lead on this disease. The AdaptDx, for us, has really given us the missing piece of the diagnosis. Prior to the AdaptDx we were able to to identify risk factors. We’re able to identify the red flags. The AdaptDx now gives me a diagnosis
ahead of time where the risk factors still come into play but they helped
drive the need to do the dark adaptometry with the AdaptDx. And further the
testing as opposed to just monitoring the risk factors over time and waiting until
it gets bad. We need to do a much better job of taking care of the disease earlier
in the process and now that we have the AdaptDx to do that I think this is
really going to change the entire way that we we approach and treat the
early diagnosis of AMD.

Leave a Reply

Your email address will not be published. Required fields are marked *